3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st

1 hour ago 1

Thomas Richmond

Tue, July 28, 2026 astatine 12:09 PM CDT 3 min read

Quick Read

ABBV trades astatine a PEG of 0.43 with a beta of conscionable 0.28, portion Skyrizi and Rinvoq combined for $6.6 cardinal successful Q1 revenue.
ABBV's 164% five-year summation dwarfs Pfizer's antagonistic 23% return, portion Merck inactive faces a 2028 Keytruda patent cliff ABBV already navigated.
AbbVie raised its quarterly dividend 5.5% to $1.73 and lifted full-year EPS guidance, signaling beardown income sum heading into the July 31 report.
Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and AbbVie didn't marque the cut. Grab the names FREE today.

AbbVie (NYSE:ABBV) enters its July 31 Q2 net study with a 2.62% dividend yield, raised net guidance, and two blockbuster drugs increasing supra 20%. Skyrizi and Rinvoq person already replaced Humira arsenic the company's maturation engines, strengthening AbbVie's lawsuit arsenic a operation of income, growth, and comparatively debased volatility.

A machine show displays a fiscal illustration for AbbVie Inc. (ABBV) successful an bureau setting. The surface shows a greenish upward-trending enactment graph with terms points from $00 to $250 connected the close Y-axis and years labeled '2026' connected the X-axis, with a circumstantial marker for 'JUL 31, 2026'. Text connected the surface reads 'AbbVie Inc. (ABBV) $259.36' and 'Dividend Yield 1.307%' with a greenish upward arrow.

AbbVie Offers Growth astatine Just 18x Forward Earnings

ABBV changes hands astatine $265.52 with a guardant P/E of 18x and a PEG of 0.43, with a beta of 0.28. Wall Street's statement people sits astatine $267.79 crossed 16 Buy and 8 Strong Buy ratings. AbbVie trades astatine a aggregate beneath the S&P 500 mean paired with maturation prospects and astir a 4th of the market's volatility.

A 5.5% Dividend Increase Strengthens the Income Case

AbbVie's annualized dividend of $6.74 per stock means the banal offers a 2.62% yield. The astir caller quarterly hike lifted the payout to $1.73 from $1.64, a 5.5% raise. Management raised full-year adjusted EPS guidance to $14.08 to $14.28 and pointed to Q2 EPS of $3.74 to $3.78 connected astir $16.7 cardinal successful revenue.

Skyrizi and Rinvoq Have Become $32 Billion Growth Engines

Skyrizi deed $4.48 cardinal successful Q1 2026 (up 30.9% YoY) and Rinvoq added $2.12 cardinal (up 23.3%). Management raised full-year Skyrizi guidance to $21.6 cardinal and Rinvoq to $10.2 billion. CEO Rob Michael said flatly, "We expect to exceed the highest consensus that's successful those models."

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and AbbVie didn't marque the cut. Grab the names FREE today.

AbbVie Has Already Crossed the Patent Cliff Facing Merck

Pfizer (NYSE:PFE) has returned -22.52% implicit 5 years and is up conscionable 3.67% year-to-date, versus ABBV's 163.87% five-year and 16.19% YTD return, with acold weaker top-line momentum.

Merck (NYSE:MRK) has rallied hard (61.08% successful 1 year), but it carries a Keytruda attraction occupation and a 2028 patent cliff. ABBV has already crossed the biosimilar vale Merck is walking toward.

Read Entire Article